AARD Key Statistics, Chart & Performance
The current stock price of AARD is 14.26 USD. In the past month the price increased by 52.19%.
AARD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.98 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20.02 | 500.60B | ||
| MRK | MERCK & CO. INC. | 12.08 | 264.21B | ||
| PFE | PFIZER INC | 7.82 | 142.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.34 | 111.38B | ||
| ZTS | ZOETIS INC | 19.79 | 55.30B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.55 | 22.66B | ||
| VTRS | VIATRIS INC | 5.25 | 14.10B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.31 | 11.12B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.99 | 8.79B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.74B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About AARD
Company Profile
Aardvark Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in San Diego, California and currently employs 33 full-time employees. The company went IPO on 2025-02-13. The firm targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. The company is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).
Company Info
AARDVARK THERAPEUTICS INC
4370 La Jolla Village Drive, Suite 1050
San Diego CALIFORNIA US
Employees: 33
Phone: 18582257696
AARDVARK THERAPEUTICS INC / AARD FAQ
What does AARD do?
Aardvark Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in San Diego, California and currently employs 33 full-time employees. The company went IPO on 2025-02-13. The firm targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. The company is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).
What is the current price of AARD stock?
The current stock price of AARD is 14.26 USD. The price increased by 0.78% in the last trading session.
Does AARDVARK THERAPEUTICS INC pay dividends?
AARD does not pay a dividend.
What is the ChartMill technical and fundamental rating of AARD stock?
AARD has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is AARDVARK THERAPEUTICS INC (AARD) stock traded?
AARD stock is listed on the Nasdaq exchange.
Can you provide the market cap for AARDVARK THERAPEUTICS INC?
AARDVARK THERAPEUTICS INC (AARD) has a market capitalization of 310.44M USD. This makes AARD a Small Cap stock.
When does AARDVARK THERAPEUTICS INC (AARD) report earnings?
AARDVARK THERAPEUTICS INC (AARD) will report earnings on 2026-03-30.
AARD Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to AARD.
AARD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AARD. While AARD has a great health rating, there are worries on its profitability.
AARD Financial Highlights
Over the last trailing twelve months AARD reported a non-GAAP Earnings per Share(EPS) of -2.53. The EPS decreased by -185.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.61% | ||
| ROE | -39.85% | ||
| Debt/Equity | 0 |
AARD Forecast & Estimates
14 analysts have analysed AARD and the average price target is 33.09 USD. This implies a price increase of 132.07% is expected in the next year compared to the current price of 14.26.